4194 Stock Overview
Holy Stone Healthcare Co., Ltd. develops therapeutics in Taiwan.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Holy Stone Healthcare Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$17.65 |
52 Week High | NT$41.85 |
52 Week Low | NT$15.85 |
Beta | 1.41 |
1 Month Change | 5.69% |
3 Month Change | -7.15% |
1 Year Change | -56.42% |
3 Year Change | -19.36% |
5 Year Change | 16.06% |
Change since IPO | -82.90% |
Recent News & Updates
Recent updates
Shareholder Returns
4194 | TW Biotechs | TW Market | |
---|---|---|---|
7D | 2.3% | -1.1% | -0.6% |
1Y | -56.4% | -21.5% | 29.2% |
Return vs Industry: 4194 underperformed the TW Biotechs industry which returned -21.5% over the past year.
Return vs Market: 4194 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
4194 volatility | |
---|---|
4194 Average Weekly Movement | 3.8% |
Biotechs Industry Average Movement | 4.8% |
Market Average Movement | 4.7% |
10% most volatile stocks in TW Market | 8.7% |
10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4194 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4194's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | Albert Wu | www.hshc.com.tw |
Holy Stone Healthcare Co., Ltd. develops therapeutics in Taiwan. It offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. The company is also developing IBD98-M, which is in Phase IIa clinical trials for the treatment of inflammatory bowel diseases; and CA102N to treat colorectal cancer.
Holy Stone Healthcare Co., Ltd. Fundamentals Summary
4194 fundamental statistics | |
---|---|
Market cap | NT$2.17b |
Earnings (TTM) | -NT$289.37m |
Revenue (TTM) | NT$236.89m |
9.2x
P/S Ratio-7.5x
P/E RatioIs 4194 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4194 income statement (TTM) | |
---|---|
Revenue | NT$236.89m |
Cost of Revenue | NT$137.51m |
Gross Profit | NT$99.38m |
Other Expenses | NT$388.75m |
Earnings | -NT$289.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.35 |
Gross Margin | 41.95% |
Net Profit Margin | -122.15% |
Debt/Equity Ratio | 72.0% |
How did 4194 perform over the long term?
See historical performance and comparison